Safety and Tolerability of NRL-1, an Intranasal Formulation of Diazepam, in Subjects with Epilepsy in a Phase 1, Open-Label Study: Focus on Adverse Events Relevant to Clinicians and Patients
Publication/Presentation Date
4-2020
Volume
94
Issue
15
First Page
2044
Last Page
2044
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Department of Medicine
Document Type
Article
COinS